Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was $7.32 for the day, down -2.40% from the previous closing price of $7.5. In other words, the price has decreased by -$2.40 from its previous closing price. On the day, 1.03 million shares were traded. FDMT stock price reached its highest trading level at $7.65 during the session, while it also had its lowest trading level at $7.13.
Ratios:
Our analysis of FDMT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.42 and its Current Ratio is at 8.42. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On January 13, 2025, BMO Capital Markets Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $40 to $15.
On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.Morgan Stanley initiated its Underweight rating on November 21, 2024, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 20 ’25 when Gupta Ashoo sold 389 shares for $8.68 per share. The transaction valued at 3,377 led to the insider holds 46,218 shares of the business.
Bizily Scott sold 1,635 shares of FDMT for $17,822 on Dec 16 ’25. The Chief Legal Officer now owns 3,594 shares after completing the transaction at $10.90 per share. On Dec 16 ’25, another insider, SCOTT BIZILY, who serves as the Officer of the company, bought 1,635 shares for $10.95 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 418228768 and an Enterprise Value of 135428752. For the stock, the TTM Price-to-Sale (P/S) ratio is 3485.25 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 1128.573 whereas that against EBITDA is -0.608.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.98, which has changed by 0.15275586 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $12.34, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is -28.75%, while the 200-Day Moving Average is calculated to be 13.48%.
Shares Statistics:
FDMT traded an average of 974.43K shares per day over the past three months and 1313030 shares per day over the past ten days. A total of 57.14M shares are outstanding, with a floating share count of 52.01M. Insiders hold about 8.97% of the company’s shares, while institutions hold 65.82% stake in the company. Shares short for FDMT as of 1765756800 were 5023933 with a Short Ratio of 5.16, compared to 1763078400 on 5188480. Therefore, it implies a Short% of Shares Outstanding of 5023933 and a Short% of Float of 9.08.
Earnings Estimates
Its stock is currently analyzed by 10.0 different market analysts. The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.82 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.14 and -$3.9 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$3.48, with 9.0 analysts recommending between -$2.6 and -$4.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $85M to a low estimate of $85k. As of. The current estimate, 4D Molecular Therapeutics Inc’s year-ago sales were $1kFor the next quarter, 7 analysts are estimating revenue of $5.34M. There is a high estimate of $8M for the next quarter, whereas the lowest estimate is $25k.
A total of 8 analysts have provided revenue estimates for FDMT’s current fiscal year. The highest revenue estimate was $85.12M, while the lowest revenue estimate was $204k, resulting in an average revenue estimate of $37.74M. In the same quarter a year ago, actual revenue was $37kBased on 6 analysts’ estimates, the company’s revenue will be $22.58M in the next fiscal year. The high estimate is $51.3M and the low estimate is $100k.
